| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5879550 | Journal of Pain and Symptom Management | 2016 | 19 Pages |
Abstract
EPC in advanced lung cancer was associated with a nearly two-month survival advantage compared to standard oncologic care. This finding provides supportive evidence to previously published reports of survival benefit with EPC intervention. Clinical trial participation rates in advanced lung cancer are lacking, and we found more frequent clinical trial participation in the early PC group. No differences were seen in chemotherapy utilization or hospice enrollment. EPC patients' longer hospice length of stay did not compromise survival.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Jonathan D. MD, Jens PhD, Anne MD, Toby C. MD, MSCI,